Oragenics Statistics
Share Statistics
Oragenics has 12.21M shares outstanding. The number of shares has increased by 237.01% in one year.
| Shares Outstanding | 12.21M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 55.16% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.67M |
| Failed to Deliver (FTD) Shares | 334.89K |
| FTD / Avg. Volume | 71.4% |
Short Selling Information
The latest short interest is 191.09K, so 1.56% of the outstanding shares have been sold short.
| Short Interest | 191.09K |
| Short % of Shares Out | 1.56% |
| Short % of Float | 2.02% |
| Short Ratio (days to cover) | 0.43 |
Valuation Ratios
The PE ratio is -0.61 and the forward PE ratio is -0.03.
| PE Ratio | -0.61 |
| Forward PE | -0.03 |
| PS Ratio | 336.38 |
| Forward PS | null |
| PB Ratio | 4 |
| P/FCF Ratio | -1.74 |
| PEG Ratio | n/a |
Enterprise Valuation
Oragenics Inc. has an Enterprise Value (EV) of 12.99M.
| EV / Earnings | -0.63 |
| EV / Sales | 344.95 |
| EV / EBITDA | -0.62 |
| EV / EBIT | -0.62 |
| EV / FCF | -1.78 |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.1.
| Current Ratio | 2.15 |
| Quick Ratio | 2.15 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 8.98 |
| Cash Flow / Debt | -23.32 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -6.52% and return on capital (ROIC) is -598.88%.
| Return on Equity (ROE) | -6.52% |
| Return on Assets (ROA) | -4.16% |
| Return on Capital (ROIC) | -598.88% |
| Revenue Per Employee | 7.53K |
| Profits Per Employee | -4.13M |
| Employee Count | 5 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -93.54% in the last 52 weeks. The beta is 0.48, so Oragenics 's price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -93.54% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 1.01 |
| Relative Strength Index (RSI) | 48.61 |
| Average Volume (20 Days) | 469.01K |
Income Statement
In the last 12 months, Oragenics had revenue of $37.65K and earned -$20.66M in profits. Earnings per share was $-9.18.
| Revenue | 37.65K |
| Gross Profit | -15.45M |
| Operating Income | -20.90M |
| Net Income | -20.66M |
| EBITDA | -20.88M |
| EBIT | -20.90M |
| Earnings Per Share (EPS) | -9.18 |
Balance Sheet
The company has $3.48M in cash and $322.51K in debt, giving a net cash position of $3.16M.
| Cash & Cash Equivalents | 3.48M |
| Total Debt | 322.51K |
| Net Cash | 3.16M |
| Retained Earnings | -206.22M |
| Total Assets | 5.20M |
| Working Capital | 1.99M |
Cash Flow
In the last 12 months, operating cash flow was -$7.29M and capital expenditures $0, giving a free cash flow of -$7.29M.
| Operating Cash Flow | -7.29M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.29M |
| FCF Per Share | -3.24 |
Margins
Gross margin is -41.04K%, with operating and profit margins of -55.52K% and -54.86K%.
| Gross Margin | -41.04K% |
| Operating Margin | -55.52K% |
| Pretax Margin | -54.86K% |
| Profit Margin | -54.86K% |
| EBITDA Margin | -55.45K% |
| EBIT Margin | -55.52K% |
| FCF Margin | -19.36K% |
Dividends & Yields
OGEN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2700% |
| FCF Yield | -176.05% |
Analyst Forecast
Currently there are no analyst rating for OGEN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 23, 2023. It was a forward split with a ratio of 60:1.
| Last Split Date | Jan 23, 2023 |
| Split Type | forward |
| Split Ratio | 60:1 |
Scores
| Altman Z-Score | -68.65 |
| Piotroski F-Score | 1 |